Holen Sie sich die Stockscreener-App
96.91
1.72%
1.64
Handel nachbörslich:
97.40
0.49
+0.51%
Schlusskurs vom Vortag:
$95.27
Offen:
$95.26
24-Stunden-Volumen:
1.20M
Relative Volume:
0.72
Marktkapitalisierung:
$19.36B
Einnahmen:
$5.36B
Nettoeinkommen (Verlust:
$1.43B
KGV:
13.70
EPS:
7.0718
Netto-Cashflow:
$1.42B
1W Leistung:
+2.39%
1M Leistung:
+2.77%
6M Leistung:
+3.67%
1J Leistung:
+56.23%
1-Tages-Spanne:
$94.81
$97.05
1-Wochen-Bereich:
$92.79
$102.86
52-Wochen-Spanne:
$57.77
$112.29
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
96.91 | 19.36B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Sanctuary Advisors LLC Has $3.16 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Gains FDA Approval for Jakafi XR Treatment - GuruFocus
FDA approves Incyte’s once-daily Jakafi XR formulation - Investing.com
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease - ChartMill
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte: Strong Business, But Risks Remain (NASDAQ:INCY) - Seeking Alpha
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
INCY Q1 earnings and revenues beat estimates on higher product sales - MSN
INCY SWOT Analysis: Strong Financial Performance Revealed in 10-Q Filing - GuruFocus
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Vanguard Capital Management (INCY) discloses 6.32% ownership in Incyte Corp - Stock Titan
GC Wealth Management RIA LLC Takes Position in Incyte Corporation $INCY - MarketBeat
Vanguard Group Inc. Sells 40,189 Shares of Incyte Corporation $INCY - MarketBeat
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
INCY Maintained by Oppenheimer -- Price Target Raised to $90 - GuruFocus
Stifel raises Incyte stock price target to $123 on earnings beat By Investing.com - Investing.com India
Stifel raises Incyte stock price target to $123 on earnings beat - Investing.com Australia
Incyte to Present at Upcoming May 2026 Investor Conferences - BioSpace
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
INCY Maintained by Stifel -- Price Target Raised to $123 - GuruFocus
Stifel Nicolaus Increases Incyte (NASDAQ:INCY) Price Target to $123.00 - MarketBeat
H.C. Wainwright reiterates Incyte stock rating on Jakafi outlook - Investing.com
Incyte Corporation (NASDAQ:INCY) Q1 2026 Earnings Call Transcript - Insider Monkey
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising Pipeline Developments - GuruFocus
INCY Financials: Income Statement, Balance Sheet & Cash Flow | Incyte Corp - Stock Titan
Morgan Stanley raises Incyte stock price target on solid results By Investing.com - Investing.com Nigeria
Oppenheimer raises Incyte stock price target on earnings beat By Investing.com - Investing.com South Africa
Oppenheimer raises Incyte stock price target on earnings beat - Investing.com
Morgan Stanley raises Incyte stock price target on solid results - Investing.com UK
Incyte Welcomes Suky Upadhyay as EVP, CFO - Contract Pharma
[ARS] INCYTE CORP SEC Filing - Stock Titan
Incyte (NASDAQ: INCY) posts 2025 growth, outlines pipeline and pay plan - Stock Titan
Robust Q1 2026 growth at Incyte (NASDAQ: INCY) driven by key drug sales - Stock Titan
TD Cowen raises Incyte stock price target to $124 on demand outlook - Investing.com
Incyte (INCY) Reports Strong Q1 2026 Sales Growth and Strategic Developments - GuruFocus
Incyte (INCY) Q1 2026 Earnings Call Transcript - The Globe and Mail
Incyte (INCY) Q2 2025 Earnings Transcript - The Globe and Mail
Incyte Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Incyte (INCY) Exceeds Q1 2026 Earnings Expectations with Strong Drug Demand - GuruFocus
Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer - BioSpace
Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
INCY Q1 Earnings and Revenues Beat Estimates on Higher Product Sales - Yahoo Finance
Incyte (NASDAQ:INCY) Announces Earnings Results, Beats Expectations By $0.47 EPS - MarketBeat
Incyte Q1 Earnings Call Highlights - MarketBeat
Incyte Q1 2026 slides: 21% revenue growth, portfolio diversification accelerates - Investing.com
Earnings call transcript: Incyte Q1 2026 beats earnings expectations - Investing.com
Compared to Estimates, Incyte (INCY) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Incyte (INCY) Reports Strong Q1 Earnings with Significant Revenue Growth - GuruFocus
Incyte (INCY) Posts Strong Q1 Revenue and Plans for New Product Launches - GuruFocus
Incyte's strong Q1 beat contrasts with QIAGEN outlook cut - MSN
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Incyte Corp-Aktie (INCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | President, Global Head of R&D |
Apr 17 '26 |
Sale |
96.50 |
18,667 |
1,801,366 |
262,692 |
| Meury William | Chief Executive Officer |
Apr 15 '26 |
Option Exercise |
0.00 |
125,000 |
0 |
161,101 |
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):